Upgrades - JPMorgan upgraded Outfront Media (OUT) to Overweight from Neutral with a price target of $25, up from $19, citing the out-of-home channel as the most resilient traditional advertising market with improved momentum in Q3 [2] - Guggenheim upgraded Grail (GRAL) to Buy from Neutral with a price target of $100, noting that while Galleri is not a perfect test, it remains the leading commercially available MCED test with a significant data moat [3] - Piper Sandler upgraded Floor & Decor (FND) to Overweight from Neutral with a price target of $80, up from $75, highlighting potential for comparable sales improvement by Q1 of 2026 [4] - KeyBanc upgraded Progyny (PGNY) to Overweight from Sector Weight with a price target of $30, indicating limited share downside and several positive catalysts over the next 12 months [4] - KeyBanc upgraded AT&T (T) to Overweight from Sector Weight with a price target of $30, attributing the recent share pullback to overblown wireless competition concerns [5] Downgrades - Raymond James downgraded Bath & Body Works (BBWI) to Market Perform from Outperform, stating that the company's growth will be below its long-term potential due to slow improvements in digital capabilities and distribution [6] - Wolfe Research downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform, citing safety issues with nexiguran ziclumeran as a hindrance to the bull thesis [6] - Raymond James double downgraded Brighthouse Financial (BHF) to Market Perform from Strong Buy, referencing the announcement of its acquisition deal for $70 per share [6] - Raymond James double downgraded Centerspace (CSR) to Market Perform from Strong Buy, noting that while the portfolio is attractive for potential buyers, the recent rally has closed the valuation gap with multifamily peers [6] - Northland downgraded QuickLogic (QUIK) to Market Perform from Outperform, maintaining a price target of $5.95, after the company reported revenue in line with guidance and uncertainty regarding a $3M contract [6]

Core Insights - Rocket Doctor has partnered with Melanoma Canada to enhance follow-up care for patients identified as at-risk during mobile skin cancer screenings across Canada [1][4][5] - Skin cancer is the most prevalent cancer in Canada, with 1 in 3 cancer diagnoses being skin-related, highlighting the urgent need for timely follow-up care [2][7][8] Company Overview - Rocket Doctor is a technology-driven digital health platform that enables physicians to manage virtual or hybrid practices, focusing on underserved communities [10] - The partnership with Melanoma Canada aims to streamline the referral process for patients without family doctors, ensuring they receive timely access to care [1][5][6] Industry Context - The Mole Mobile campaign provides free skin cancer screenings in various communities, addressing the high incidence of skin cancer in Canada [2][5] - The initiative is expected to increase patient traffic on Rocket Doctor's platform, reinforcing its mission to improve equitable access to healthcare [3][8]